European Journal of Cancer Care · 2008 · 12 citations · 31 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesB Cell ActivationCancer ImmunotherapyCell-based ImmunotherapyCell-mediated ImmunityT Cell ActivationAntigen Presenting CellsAntigen-specific Immune ResponseAntigen-specific T Cell ResponsesCd8 Positive T Cell ResponsesCd8 Positive T CellsT Cell-based ImmunotherapyT-cell Responses To Tumor AntigensTumor-specific T Cell Activation
Hepatocellular carcinoma (HCC) is one of the incurable tumours in the world. Cell-based immunotherapy, in which antigen-loaded antigen-presenting cells (APCs) are able to elicit T cell responses, has become an alternative treatment for liver cancer. Here, we used HepG2 cells' total RNA-electroporated CD40 ligand-activated B (CD40-B) cells as alternative APC for induction of specific CD8+ T-cell responses. The antigen-presenting ability of CD40-B cells was determined by phenotypic analysis, showing a polyclonal, strongly activated B-cell population with high expression of co-stimulatory molecules. To demonstrate the ability of total RNA extracted from HepG2 cells electroporated CD40-B cells to induce CD8+ T-cell responses, these RNA-loaded cells were co-cultured with autologous peripheral blood mononuclear cells for 7 days followed by analysis of T-cell antigen specificity. These experiments showed that CD40-B cells electroporated with HepG2 cells' total RNA are capable of activating antigen-specific interferon-gamma-producing CD8+ T cells, and these T cells activated by CD40-B cells show a killing effect on HepG2 cells. These findings demonstrated that the carcinoma cell derived total RNA-electroporated CD40-B cells could be used as alternative APC for the induction of antigen-specific CD8+ T-cell responses, which might be used in HCC immunotherapy.
31
Estimating the world cancer burden: Globocan 2000
D. Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · International Journal of Cancer · 2001 · 3.7K citations · Full text
Josep M. Llovet, Andrew K. Burroughs, Jordi Bruix · The Lancet · 2003 · 3.6K citations
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Stephen P. Schoenberger, René E. M. Toes, Ellen I. H. van der Voort et al. · Nature · 1998 · 2.6K citations